468 related articles for article (PubMed ID: 18294997)
1. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.
; Beral V; Doll R; Hermon C; Peto R; Reeves G
Lancet; 2008 Jan; 371(9609):303-14. PubMed ID: 18294997
[TBL] [Abstract][Full Text] [Related]
2. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies.
Collaborative Group on Epidemiological Studies on Endometrial Cancer
Lancet Oncol; 2015 Sep; 16(9):1061-1070. PubMed ID: 26254030
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.
Collaborative Group on Hormonal Factors in Breast Cancer
Lancet; 1996 Jun; 347(9017):1713-27. PubMed ID: 8656904
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer.
Contraception; 1996 Sep; 54(3 Suppl):1S-106S. PubMed ID: 8899264
[TBL] [Abstract][Full Text] [Related]
5. Oral contraceptives and ovarian cancer: an update, 1998-2004.
La Vecchia C
Eur J Cancer Prev; 2006 Apr; 15(2):117-24. PubMed ID: 16523008
[TBL] [Abstract][Full Text] [Related]
6. Epithelial ovarian cancer and combination oral contraceptives.
Rosenberg L; Shapiro S; Slone D; Kaufman DW; Helmrich SP; Miettinen OS; Stolley PD; Rosenshein NB; Schottenfeld D; Engle RL
JAMA; 1982 Jun; 247(23):3210-2. PubMed ID: 7045417
[TBL] [Abstract][Full Text] [Related]
7. Oral contraceptives and ovarian cancer.
La Vecchia C; Franceschi S
Eur J Cancer Prev; 1999 Aug; 8(4):297-304. PubMed ID: 10493304
[TBL] [Abstract][Full Text] [Related]
8. Noncontraceptive health benefits of oral steroidal contraceptives.
Mishell DR
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):809-16. PubMed ID: 7065059
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses' Health Study.
Colditz GA
Ann Intern Med; 1994 May; 120(10):821-6. PubMed ID: 8154642
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.
; Appleby P; Beral V; Berrington de González A; Colin D; Franceschi S; Goodhill A; Green J; Peto J; Plummer M; Sweetland S
Lancet; 2007 Nov; 370(9599):1609-21. PubMed ID: 17993361
[TBL] [Abstract][Full Text] [Related]
11. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
[TBL] [Abstract][Full Text] [Related]
12. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.
Iversen L; Fielding S; Lidegaard Ø; Mørch LS; Skovlund CW; Hannaford PC
BMJ; 2018 Sep; 362():k3609. PubMed ID: 30257920
[TBL] [Abstract][Full Text] [Related]
13. Worldwide variations in the lifetime probability of reproductive cancer in women: implications of best-case, worst-case, and likely-case assumptions about the effect of oral contraceptive use.
Petitti DB; Porterfield D
Contraception; 1992 Feb; 45(2):93-104. PubMed ID: 1559340
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of oral contraceptives on ovarian cancer risk.
Bosetti C; Negri E; Trichopoulos D; Franceschi S; Beral V; Tzonou A; Parazzini F; Greggi S; La Vecchia C
Int J Cancer; 2002 Nov; 102(3):262-5. PubMed ID: 12397647
[TBL] [Abstract][Full Text] [Related]
15. Oral contraceptives as related to cancer and benign lesions of the breast.
Fasal E; Paffenbarger RS
J Natl Cancer Inst; 1975 Oct; 55(4):767-73. PubMed ID: 1185801
[TBL] [Abstract][Full Text] [Related]
16. An epidemiologic study of ovarian cancer. Part 11: Oral contraceptive use and menstrual events.
Badawy YA; Bayoumi DM
J Egypt Public Health Assoc; 1992; 67(5-6):579-91. PubMed ID: 1294683
[TBL] [Abstract][Full Text] [Related]
17. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions.
Ness RB; Grisso JA; Klapper J; Schlesselman JJ; Silberzweig S; Vergona R; Morgan M; Wheeler JE
Am J Epidemiol; 2000 Aug; 152(3):233-41. PubMed ID: 10933270
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and breast, endometrial, and ovarian cancers. The Cancer and Steroid Hormone Study Group, Atlanta Georgia.
Gwinn ML
J Obstet Gynaecol (Lahore); 1985 Jan; 5 Suppl 2():S83-7. PubMed ID: 12268773
[TBL] [Abstract][Full Text] [Related]
19. The reduction in risk of ovarian cancer associated with oral-contraceptive use.
Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
N Engl J Med; 1987 Mar; 316(11):650-5. PubMed ID: 3821795
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for epithelial ovarian tumours of borderline malignancy.
Parazzini F; Restelli C; La Vecchia C; Negri E; Chiari S; Maggi R; Mangioni C
Int J Epidemiol; 1991 Dec; 20(4):871-7. PubMed ID: 1800425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
